Sort   by:  
 Page size 
UnknownLack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity.
Not available
S-EPMC103888 | biostudies-literature
UnknownDifferences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.
Not available
S-EPMC10017795 | biostudies-literature
UnknownGenetically delivered antibody protects against West Nile virus.
Not available
S-EPMC2267767 | biostudies-literature
UnknownComparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.
Not available
S-EPMC4514049 | biostudies-literature
UnknownSafety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Not available
S-EPMC5783347 | biostudies-literature
UnknownInfluenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
Not available
S-EPMC3491556 | biostudies-literature
UnknownSafety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.
Not available
S-EPMC4318920 | biostudies-literature
UnknownPhase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.
Not available
S-EPMC4751067 | biostudies-literature
UnknownPrime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.
Not available
S-EPMC3699006 | biostudies-literature
UnknownDNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.
Not available
S-EPMC7185472 | biostudies-literature
Sort   by:  
 Page size